Keros Therapeutics, Inc. (KROS)

Import this data to Google Sheets with:

=jivedata("KROS","financials")

Full statements spill as a table. For one cell: =jivedata("KROS","Revenue") or =jivedata("KROS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Keros Therapeutics, Inc.

KROS • CIK 0001664710

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-169,941	$-210,833	$67,569	$-101,468
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-152,992	$-187,053	$91,897	$-86,097
Income Tax Expense (Benefit)	$0	$300	$4,883	$-2,938
Net Income (Loss) Attributable to Parent	$-152,992	$-187,353	$87,014	$-83,159
Weighted Average Number of Shares Outstanding, Basic	29,447,119	37,437,652	37,221,211	16,350,517
Weighted Average Number of Shares Outstanding, Diluted	29,447,119	37,437,652	37,859,106	16,420,933
Revenue from Contract with Customer, Excluding Assessed Tax	$151	$3,550	$244,061	$15,014
Research and Development Expense	$135,258	$173,629	$129,643	$75,859
General and Administrative Expense	$34,834	$40,754	$46,849	$40,623
Operating Expenses	$170,092	$214,383	$176,492	$116,482
Dividend Income, Operating	$14,755	$23,496	$24,867	$15,577
Other Nonoperating Income (Expense)	$-206	$-954	$-539	$-206
Nonoperating Income (Expense)	$16,949	$23,780	$24,328	$15,371

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Lease, Right-of-Use Asset	$15,334	$19,251	$16,841	$15,553
Property, Plant and Equipment, Net	$4,134	$4,237	$4,297	$3,715
Restricted Cash, Noncurrent	$1,212	$1,449	$1,449	$1,449
Other Assets, Noncurrent	$2,052	$2,056	$0	$0
Assets	$370,025	$615,886	$338,021	$287,600
Operating Lease, Liability, Noncurrent	$13,439	$16,883	$14,475	$13,127
Liabilities	$37,812	$44,333	$34,889	$25,280
Cash and Cash Equivalents, at Carrying Value	$331,147	$559,931	$287,415	$257,606
Accounts Receivable, after Allowance for Credit Loss, Current	$143	$2,742	$3,567	$0
Prepaid Expense and Other Assets, Current	$16,003	$26,220	$22,202	$7,027
Income Taxes Receivable, Current	—	—	$2,250	$2,250
Assets, Current	$347,293	$588,893	$315,434	$266,883
Accounts Payable, Current	$5,450	$4,602	$1,967	$1,816
Operating Lease, Liability, Current	$1,005	$1,978	$2,408	$2,597
Accrued Liabilities, Current	$17,918	$20,870	$16,039	$7,740
Liabilities, Current	$24,373	$27,450	$20,414	$12,153
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$3	$4	$4	$4
Treasury Stock, Common, Value	—	—	$384,558	$384,558
Additional Paid in Capital	$713,636	$1,140,328	$1,169,451	$1,181,057
Retained Earnings (Accumulated Deficit)	$-381,426	$-568,779	$-481,765	$-534,183
Stockholders' Equity Attributable to Parent	$332,213	$571,553	$303,132	$262,320
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	200,000,000	200,000,000	200,000,000	200,000,000
Common Stock, Shares, Issued	31,841,084	40,554,705	40,670,466	40,953,948
Common Stock, Shares, Outstanding	31,841,084	40,554,705	19,543,706	19,827,188
Treasury Stock, Common, Shares	—	—	21,126,760	21,126,760

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$51,984	$229,021	$-272,516	$-432,609
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$332,359	$561,380	$288,864	$-150,180
Net Income (Loss) Attributable to Parent	$-152,992	$-187,353	$87,014	$-83,159
Net Cash Provided by (Used in) Operating Activities	$-124,508	$-160,869	$107,505	$-47,993
Payments to Acquire Property, Plant, and Equipment	$2,464	$1,931	$1,551	$494
Net Cash Provided by (Used in) Investing Activities	$-2,464	$-1,931	$-1,551	$-494
Payments of Stock Issuance Costs	—	$171	$0	$0
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised	—	—	$138	$138
Payments for Repurchase of Common Stock	—	—	$375,000	$375,000
Proceeds from Stock Options Exercised	$3,225	$12,141	$150	$159
Net Cash Provided by (Used in) Financing Activities	$178,956	$391,821	$-378,470	$-384,122
Income Taxes Paid, Net	—	—	$7,145	$5,645
Capital Expenditures Incurred but Not yet Paid	$599	$0	$5	$-9
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$1,338	$5,737	$0	$0
Cash and Cash Equivalents, at Carrying Value	$331,147	$559,931	$287,415	$-151,629
Restricted Cash	$1,212	$1,449	$1,449	$1,449
Depreciation	$815	$1,229	$1,509	$1,600
Gain (Loss) on Disposition of Property Plant Equipment	$-4	$0	$13	$-1
Share-based Payment Arrangement, Noncash Expense	$28,763	$34,872	$28,696	$22,867
Operating Lease, Right-of-Use Asset, Amortization Expense	$1,552	$1,820	$2,410	$2,519
Increase (Decrease) in Accounts Receivable	$143	$2,599	$825	$-15,816
Increase (Decrease) in Prepaid Expense and Other Assets	$9,284	$10,217	$-4,018	$-19,750
Increase (Decrease) in Income Taxes Receivable	—	—	$2,250	$2,250
Increase (Decrease) in Other Operating Assets	$478	$4	$-2,056	$0
Increase (Decrease) in Accounts Payable	$1,614	$-249	$-3,001	$-3,437
Increase (Decrease) in Accrued Liabilities	$5,257	$2,952	$-10,131	$-12,224

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("KROS","financials")

Full statements spill as a table. For one cell: =jivedata("KROS","Revenue") or =jivedata("KROS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.